Comparative Pharmacology
Head-to-head clinical analysis: QUINALAN versus QUINIDINE GLUCONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QUINALAN versus QUINIDINE GLUCONATE.
QUINALAN vs QUINIDINE GLUCONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Quinidine (the active ingredient in Quinalan) is a class Ia antiarrhythmic agent that binds to and blocks voltage-gated sodium channels in cardiac myocytes, prolonging the action potential duration and effective refractory period. It also has vagolytic effects and blocks potassium channels.
Class Ia antiarrhythmic agent; blocks sodium channels (Nav1.5) and potassium channels (IKr, IKs), prolongs action potential duration and effective refractory period; also has anticholinergic and alpha-adrenergic blocking effects.
10 mg orally once daily, may increase to 20 mg after 2 weeks if needed.
324-648 mg orally every 8-12 hours; maximum 3.24 g/day. Also administered IV as quinidine gluconate 200-400 mg (diluted) at a rate ≤1 mL/min.
None Documented
None Documented
Terminal half-life: 12 hours (range 10-14) in normal renal function; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 6-8 hours (range 4-12 hours) in healthy adults; prolonged in HF, renal impairment, or elderly.
Renal: 60% unchanged; Biliary/fecal: 30% as metabolites; 10% other.
Renal: 50-70% unchanged; Biliary/fecal: 20-30%; Hepatic metabolism accounts for 10-30%.
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)